This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand how somatic mutations in acute myeloid leukemia (AML) disrupt cardiac metabolism and lead to cardiomyopathy. The $549,796 award to Cedars-Sinai Medical Center aims to examine alterations in heart oxidative metabolism, the impact of reductive carboxylation on epigenetic remodeling, and sex differences in cardiomyopathy development due to AML-associated TET2 and IDH2 mutations. The research leverages clinically relevant AML models and in vivo/ex vivo cardiac metabolism studies to uncover the mechanisms linking leukemia metabolic dysregulation and heart failure, with the goal of identifying more effective treatments. This funding builds on the medical center's expertise in biomedical research on cardiovascular diseases, cancer, and the emerging field of cardio-oncometabolism.
Generated 3/18/25, 2:05 AM